Witnesses Seek 15% Boost For NCI In 1998 as First Step to 100% Raise Over 5 Years
In Brief: visco Named to Cancer Policy Board; Foundation Pledges $6.5 Million to Karmanos
In This Issue: Congressional Testimony On NIH, NCI Appropriations, FDA Reform
Patient Advocates; NBCC Delivers 2.6M Signatures, demands 2.6Billion
NIH director; Targets Increases Favor Established Researchers
Pharmaceutical Industry: IVAX Official Broder Objects To Orphan Drug Policies of FDA
National Academy elects New Members
Trending Stories
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe - At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer
- Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival
- Daraxonrasib’s success in treating pancreatic cancer is a reminder that clinical cancer researchers are heroes
- Pam Bondi diagnosed with thyroid cancer
- Political appointees to be inserted into all stages of making research funding awards if OMB rule becomes final









